17-31327791-T-G
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_001042492.3(NF1):c.5561T>G(p.Leu1854Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L1854P) has been classified as Likely pathogenic.
Frequency
Consequence
NM_001042492.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NF1 | NM_001042492.3 | c.5561T>G | p.Leu1854Arg | missense_variant | 38/58 | ENST00000358273.9 | NP_001035957.1 | |
NF1 | NM_000267.3 | c.5498T>G | p.Leu1833Arg | missense_variant | 37/57 | NP_000258.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NF1 | ENST00000358273.9 | c.5561T>G | p.Leu1854Arg | missense_variant | 38/58 | 1 | NM_001042492.3 | ENSP00000351015.4 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Neurofibromatosis, type 1 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Mar 15, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Apr 25, 2016 | In summary, this variant is absent from the population and has been observed to occur de novo in an affected individual. Therefore, it has been classified as Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a NF1-related disease. However, this variant has been observed in an individual affected with neurofibromatosis type 1, and family studies indicate this variant likely was not inherited from either parent (i.e. occurred de novo) (Invitae database). This sequence change replaces leucine with arginine at codon 1833 of the NF1 protein (p.Leu1833Arg). The leucine residue is moderately conserved and there is a moderate physicochemical difference between leucine and arginine. - |
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 03, 2019 | The p.L1833R pathogenic mutation (also known as c.5498T>G), located in coding exon 37 of the NF1 gene, results from a T to G substitution at nucleotide position 5498. The leucine at codon 1833 is replaced by arginine, an amino acid with dissimilar properties. This variant has been detected de novo in an individual with neurofibromatosis type 1 (Ambry internal data). A different alteration at this same position, p.L1833P, has been reported in an individual with clinical features or a clinical diagnosis of NF1 (Xu W et al. Int. J. Mol. Med., 2014 Jul;34:53-60). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this variant is classified as a pathogenic mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at